EleFirst Science & Technology Co Ltd
SZSE:300356
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EleFirst Science & Technology Co Ltd
Cash from Operating Activities
EleFirst Science & Technology Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EleFirst Science & Technology Co Ltd
SZSE:300356
|
Cash from Operating Activities
-¥74.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Raytron Technology Co Ltd
SSE:688002
|
Cash from Operating Activities
¥1.9B
|
CAGR 3-Years
55%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
Universal Scientific Industrial Shanghai Co Ltd
SSE:601231
|
Cash from Operating Activities
¥2.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Hangzhou Hikvision Digital Technology Co Ltd
SZSE:002415
|
Cash from Operating Activities
¥24.9B
|
CAGR 3-Years
32%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
|
Zhonghang Electronic Measuring Instruments Co Ltd
SZSE:300114
|
Cash from Operating Activities
-¥141m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Huagong Tech Co Ltd
SZSE:000988
|
Cash from Operating Activities
¥1.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
27%
|
CAGR 10-Years
20%
|
|
EleFirst Science & Technology Co Ltd
Glance View
EleFirst Science & Tech Co., Ltd. engages in the development, manufacture, and sale of intelligent information collection systems. The company is headquartered in Nanjing, Jiangsu and currently employs 478 full-time employees. The company went IPO on 2012-09-24. The firm is principally involved in the research, development, manufacture and sale of pharmaceutical products. The firm's main products include compound dichloroacetic acid diisopropylamine for injection, amifostine for injection, clindamycin phosphate for injection and urokinase for injection. The firm distributes its products in domestic market.
See Also
What is EleFirst Science & Technology Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-74.8m
CNY
Based on the financial report for Mar 31, 2023, EleFirst Science & Technology Co Ltd's Cash from Operating Activities amounts to -74.8m CNY.
What is EleFirst Science & Technology Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-24%
